Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Background. Kidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19. Methods. We analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021. Results. We included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status. Conclusions. In kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.
Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months after a Diagnosis of COVID-19
Duivenvoorden R.;Vart P.;Noordzij M.;Soares Dos Santos A. C.;Zulkarnaev A. B.;Franssen C. F. M.;Kuypers D.;Demir E.;Rahimzadeh H.;Kerschbaum J.;Jager K. J.;Turkmen K.;Hemmelder M. H.;Schouten M.;Rodriguez-Ferrero M. L.;Crespo M.;Gansevoort R. T.;Hilbrands L. B.;Van Der Net J. B.;Essig M.;Du Buf-Vereijken P. W. G.;Van Ginneken B.;Maas N.;Vogt L.;Van Jaarsveld B. C.;Bemelman F. J.;Klingenberg-Salahova F.;Heenan-Vos F.;Vervloet M. G.;Nurmohamed A.;Abramowicz D.;Verhofstede S.;Maoujoud O.;Malfait T.;Fialova J.;Melilli E.;Fava A.;Cruzado J. M.;Montero Perez N.;Lips J.;Krepel H.;Adilovic H.;Hengst M.;Konings C.;Rydzewski A.;Braconnier P.;Weis D.;Gellert R.;Oliveira J.;Alferes D. G.;Radulescu D.;Zakharova E. V.;Ambuehl P. M.;Guidotti R.;Walker A.;Lepeytre F.;Rabate C.;Rostoker G.;Marques S.;Azasevac T.;Strazmester Majstorovic G.;Katicic D.;Ten Dam M.;Kruger T.;Brzosko S.;Liakopoulos V.;Zanen A. L.;Logtenberg S. J. J.;Fricke L.;Kuryata O.;Slebe J. J. P.;Abd Elhafeez S.;Kemlin D.;Van De Wetering J.;Reinders M. E. J.;Hesselink D. A.;Kal-Van Gestel J.;Eiselt J.;Kielberger L.;El-Wakil H. S.;Verhoeven M.;Logan I.;Canal C.;Facundo C.;Ramos A. M.;Debska-Slizien A.;Veldhuizen N. M. H.;Tigka E.;Polyzou Konsta M. A.;Panagoutsos S.;Mallamaci F.;Postorino A.;Cambareri F.;Matceac I.;Nistor I.;Covic A.;Groeneveld J. H. M.;Jousma J.;Van Buren M.;Diekmann F.;Oppenheimer F.;Blasco M.;Assis Pereira T.;Arias-Cabrales C.;Llinas-Mallol L.;Buxeda A.;Tarrega C. B.;Redondo-Pachon D.;Jimenez M. D. A.;Mendoza-Valderrey A.;Martins A. C.;Mateus C.;Alvila G.;Laranjinha I.;Hofstra J. M.;Siezenga M. A.;Franco A.;Arroyo D.;Castellano S.;Balda Manzanos S.;Sosa Barrios R. H.;Lemahieu W.;Bartelet K.;Burak Dirim A.;Sukru Sever M.;Turkmen A.;Safak S.;Hollander D. A. M. J.;Buttner S.;De Vries A. P. J.;Meziyerh S.;Van Der Helm D.;Mallat M.;Bouwsma H.;Sridharan S.;Petruliene K.;Maloney S. -R.;Verberk I.;Van Der Sande F. M.;Christiaans M. H. L.;Mohan Kumar N.;Di Luca M.;Tuglular S. Z.;Kramer A.;Beerenhout C.;Luik P. T.;Tiefenthaler M.;Watschinger B.;Adema A. Y.;Stepanov V. A.;Gandolfini I.;Maggiore U.;Fliedner A.;Asberg A.;Mjoen G.;Miyasato H.;De Fijter C. W. H.;Mongera N.;Pini S.;De Biase C.;Kerckhoffs A.;Van De Logt A. E.;Maas R.;Lebedeva O.;Lopez V.;Reichert L. J. M.;Verhave J.;Titov D.;Parshina E. V.;Zanoli L.;Marcantoni C.;Van Kempen G.;Van Gils-Verrij L. E. A.;Harty J. C.;Meurs M.;Myslak M.;Battaglia Y.;Lentini P.;Den Deurwaarder E.;Stendahl M.;Rychlik I.;Cabezas-Reina C. J.;Maria Roca A.;Nauta F.;Sahin I.;Goffin E.;Kanaan N.;Labriola L.;Devresse A.;Diaz-Mareque A.;Coca A.;De Arriba G.;Meijers B. K. I.;Naesens M.;Desschans B.;Tonnerlier A.;Wissing K. M.;Dedinska I.;Pessolano G.;Malik S.;Dounousi E.;Papachristou E.;Berger S. P.;Meijer E.;Sanders J. S. F.;Ozyilmaz A.;Buturovic Ponikvar J.;Marn Pernat A.;Kovac D.;Arnol M.;Ekart R.;Abrahams A. C.;Molenaar F. M.;Van Zuilen A. D.;Meijvis S. C. A.;Dolmans H.;Tantisattamo E.;Esposito P.;Krzesinski J. -M.;Barahira J. D.;Gallieni M.;Martin-Moreno P. L.;Guglielmetti G.;Guzzo G.;Toapanta N.;Jose Soler M.;Luik A. J.;Van Kuijk W. H. M.;Stikkelbroeck L. W. H.;Hermans M. M. H.;Rimsevicius L.;Righetti M.;Islam M.;Heitink-Ter Braak N.
2022-01-01
Abstract
Background. Kidney transplant patients are at high risk for coronavirus disease 2019 (COVID-19)-related mortality. However, limited data are available on longer-term clinical, functional, and mental health outcomes in patients who survive COVID-19. Methods. We analyzed data from adult kidney transplant patients in the European Renal Association COVID-19 Database who presented with COVID-19 between February 1, 2020, and January 31, 2021. Results. We included 912 patients with a mean age of 56.7 (±13.7) y. 26.4% were not hospitalized, 57.5% were hospitalized without need for intensive care unit (ICU) admission, and 16.1% were hospitalized and admitted to the ICU. At 3 mo follow-up survival was 82.3% overall, and 98.8%, 84.2%, and 49.0%, respectively, in each group. At 3 mo follow-up biopsy-proven acute rejection, need for renal replacement therapy, and graft failure occurred in the overall group in 0.8%, 2.6%, and 1.8% respectively, and in 2.1%, 10.6%, and 10.6% of ICU-admitted patients, respectively. Of the surviving patients, 83.3% and 94.4% reached their pre-COVID-19 physician-reported functional and mental health status, respectively, within 3 mo. Of patients who had not yet reached their prior functional and mental health status, their treating physicians expected that 79.6% and 80.0%, respectively, still would do so within the coming year. ICU admission was independently associated with a low likelihood to reach prior functional and mental health status. Conclusions. In kidney transplant recipients alive at 3-mo follow-up, clinical, physician-reported functional, and mental health recovery was good for both nonhospitalized and hospitalized patients. Recovery was, however, less favorable for patients who had been admitted to the ICU.
Adult Humans Intensive Care Units Middle Aged Outcome Assessment, Health Care Retrospective Studies SARS-CoV-2 Transplant Recipients COVID-19 Kidney Transplantation
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/533638
Citazioni
4
5
4
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2021-2023 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
